Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab plus atorvastatin in diabetic patients with hyperlipidemia or mixed dyslipidemia
CTR20150464Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in hyperlipidemia, dyslipidemia, type 2 diabetes mellitus (T2DM), sponsored by Amgen. Started Jan 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiadyslipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20150464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150464.